How to Value a Healthcare SaaS / EMR Company in 2026

I've spent most of my healthcare M&A career on the services side — physician practices, surgery centers, post-acute — but over the last five years the healthcare technology practice has taken over. The reason is simple: specialty-specific EMR and healthcare SaaS businesses have become some of the most attractive acquisition targets in all of software. They combine the retention of vertical SaaS with the regulatory moat of healthcare.

If you run a specialty EMR, RCM platform, patient engagement tool, or clinical workflow SaaS company doing $3M to $100M in ARR, here's how buyers will actually price you and what moves the number.

Why Healthcare SaaS Trades at a Premium

Once an EMR is installed in a medical practice, displacement rates are the lowest in software. I've seen dermatology practices run the same EMR for 15 years because the cost of migrating a decade of clinical records, retraining staff, and re-credentialing payer connections simply isn't worth it unless the current system fails completely. Gross retention of 96-98% is normal in specialty EMR.

Combine that retention with ONC certification, HIPAA infrastructure, payer interfaces, and specialty-specific clinical content, and you have a business that's very hard to build and very hard to displace. Strategic buyers pay for that. When Thoma Bravo took Nextech private in 2023, the deal was reportedly in the 12-14x ARR range. When Bain Capital bought Harris Healthcare's portfolio, when EQT acquired WSO2, when Hg and TA keep adding to their healthcare software platforms — this is the template.

The Multiples by Size and Specialty

• Under $3M ARR: 4-7x ARR. Too small for most strategics; mostly PE tuck-ins into existing platforms like Nextech, ModMed, or AdvancedMD.
• $3-10M ARR, 25%+ growth: 7-11x ARR. Strategic tuck-in range. Specialty-specific EMRs in underserved niches can push higher.
• $10-40M ARR, 30%+ growth: 10-15x ARR. Platform-grade. PE sponsors pay here for category-leading specialty platforms.
• $40M+ ARR with strong unit economics: 12-18x ARR. Scarce and auctioned. Think Modernizing Medicine (ModMed), PointClickCare ($1B+ from Hellman & Friedman, later sold upward), Nextech.

Specialty matters enormously. Dermatology, ophthalmology, plastic surgery, orthopedics, and dental trade at the top of the range because those specialties have high procedure volumes, favorable reimbursement, and consolidated buyer bases (PE-backed MSOs and DSOs). Primary care and behavioral health trade a notch lower because reimbursement is tighter and practices are more fragmented. Rural hospital and FQHC software trades lower still because customer budgets are constrained.

What Drives Multiples Within the Range

Provider count and growth. The fundamental unit of value in an EMR is the active provider on the platform. Buyers will ask: how many providers are on your system today, how has that grown over 3 years, and what's your average revenue per provider? A platform charging $500 per provider per month with 2,000 providers is a $12M ARR business, but a platform charging $1,200 per provider per month with 1,000 providers is also $14M ARR and will trade higher because the ARPU supports a richer product and better unit economics.

Certifications and compliance. ONC Health IT Certification, Meaningful Use / Promoting Interoperability readiness, HITRUST, SOC 2 Type II, and HIPAA BAA coverage are all table stakes above $10M ARR. If you don't have them, buyers will price in the cost and delay of getting them. Specialty certifications (MIPS reporting, QCDR participation, state prescription drug monitoring integrations) are differentiators and drive multiple expansion.

Payer interfaces and clearinghouse connections. Direct integrations with Change Healthcare (Optum), Waystar, Availity, and major payers create real switching costs. If your platform handles eligibility checks, claim submission, ERA posting, and denial management, you're not just an EMR — you're a revenue cycle platform, and RCM functionality can double your revenue per customer. Buyers know this and price accordingly.

Attached services revenue. Many healthcare SaaS companies layer RCM services on top of software — either outsourced billing or co-sourced RCM. This revenue can be very sticky and very profitable, but it's valued differently than pure SaaS. Strategic buyers will bifurcate: software at 10-15x ARR, RCM services at 4-7x EBITDA. Keep the financials clean and presented separately or you'll leave money on the table.

AI and ambient documentation angle. Since 2023, anything involving ambient clinical documentation, AI-generated SOAP notes, or AI-powered prior authorization has seen significant multiple expansion. Microsoft's Nuance acquisition ($19.7B) and the strategic interest around DAX Copilot have re-rated the category. If you have a credible AI story, buyers will pay for it.

Who Actually Buys Healthcare SaaS

• athenahealth — owned by Bain Capital and Hellman & Friedman after a $17B take-private. Active acquirer for network expansion.
• Veradigm (formerly Allscripts) — ambulatory EHR and RCM. Consolidator in specialty EHR.
• eClinicalWorks — privately held, occasionally acquires but mostly builds internally.
• NextGen Healthcare — taken private by Thoma Bravo in 2024 for $1.8B at roughly 3x revenue on a mature asset.
• Greenway Health — specialty ambulatory EHR.
• Nextech, ModMed, AdvancedMD — specialty platforms actively rolling up adjacent tools.
• WellSky, PointClickCare, MatrixCare — post-acute and senior care software consolidators.
• Waystar, R1 RCM, Inovalon — RCM platforms acquiring adjacent workflow tools.

PE involvement is extensive and well-organized: Thoma Bravo, Bain Capital, Hellman & Friedman, TA Associates, Hg Capital, Francisco Partners, Vista Equity, Warburg Pincus, and Serent Capital all have active healthcare software theses. For sub-$30M ARR assets, PE is often the best-priced buyer because they can roll you into a platform and underwrite real synergies.

The Due Diligence Buyers Will Run

Healthcare SaaS diligence is intense. Expect 90-120 days from LOI to close, minimum. Buyers will dig deep into: HIPAA compliance history, any OCR investigations or breaches, SOC 2 reports, penetration test results, ONC certification status, subprocessor agreements, BAA coverage across your customer base, and any state-level HIT certifications. They'll also run cohort retention by specialty, NRR, provider count growth, and the financial split between SaaS, RCM services, and implementation revenue. For the fundamentals on how ARR multiples are built, see our SaaS valuation guide.

One area where healthcare diligence goes deeper than generic SaaS: clinical liability. Buyers will want to understand every clinical decision support feature, every medication interaction alert, every template — and whether any of it creates malpractice exposure for your customers. Clean documentation here saves weeks of back-and-forth during the process.

What Destroys Value in Healthcare SaaS

Any prior HIPAA breach or OCR investigation. These don't kill deals but they put a hard ceiling on multiple. Disclose early and document remediation.

Expired or weak ONC certification. If you're on an older edition of the certification criteria, buyers will price in the cost of recertification plus the risk that your customers lose MIPS eligibility.

Heavy implementation services revenue. If 30-40% of revenue is one-time implementation or data migration fees, buyers will pull that out and value it at 1-2x. Category it cleanly.

Single-specialty concentration with shrinking TAM. If your only market is a specialty that's under reimbursement pressure (primary care Medicare only, certain behavioral health niches), buyers will model revenue per provider declining and discount the multiple.

No mobile or patient-facing story. Modern EMRs need mobile access for providers and patient portals for engagement. Missing either means re-platforming cost in the buyer's model.

How to Maximize Your Exit

Start 18-24 months before a process. Three moves matter most. First, get your compliance stack airtight — current ONC certification, SOC 2 Type II, HITRUST if possible, documented HIPAA program. Second, push NRR above 110% by launching attached modules: telehealth, patient engagement, analytics, or RCM services. Third, land reference customers in your target specialty that buyers will recognize — large PE-backed MSOs, health systems, or nationally-known group practices. Those logos become the story in your CIM.

Run a real auction. Healthcare SaaS buyers are sophisticated and will pay their best number only under competition. Use a banker with deep healthcare tech relationships — the buyer pool is specialized enough that a generalist will miss 30% of the likely bidders.

The Bottom Line

Healthcare SaaS and specialty EMR is one of the most structurally attractive categories in software M&A: near-perfect retention, regulatory moats, and a deep pool of strategic and PE buyers. For a growing, certification-complete, specialty-focused platform with 110%+ NRR, 10-15x ARR is the realistic range. Know your buyers, prepare your compliance story, and run a process that lets competition drive the number.